About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, May 5th, 2015

The QualityStocks
Daily Stock List


OncoSec Medical, Inc. (ONCS)

Wall Street Resources reported recently on OncoSec Medical, Inc. (ONCS), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed OncoSec Medical, Inc. is developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors. The bio-pharmaceutical Company’s mission is to pioneer and refine new electroporation technologies, which endeavor to benefit patients and improve the quality of life for those whose skin cancers cannot be treated effectively with conventional treatment approaches. OncoSec Medical has its headquarters in San Diego, California.

OncoSec’s main technology takes advantage of a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of different skin cancers, and its potential to initiate a systemic immune response without the toxicities associated with many other systemic treatments. 

The Company’s clinical programs include three Phase II clinical trials for ImmunoPulse targeting metastatic melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. OncoSec’s lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is presently in Phase 2 development, and is taking place in collaboration with several prominent academic medical centers.

OncoSec Medical also has its NeoPulse. It utilizes the OMS system to destroy cancer cells employing less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug. Clinical trial results suggest NeoPulse may enhance local activity of the anti-cancer drug bleomycin. This is while minimizing systemic side effects. Pre-clinical and clinical data from Phase 1 through Phase 4 clinical trials demonstrate NeoPulse technology holds promise as a treatment for solid tumors.

ImmunoPulse and NeoPulse therapies represent a potential solution for less invasive and less expensive therapies that can lessen detrimental effects resulting from currently available cancer treatments. This includes surgery, systemic chemotherapy or immunotherapy, and also other treatment alternatives.

OncoSec Medical and Heat Biologics, Inc. (HTBX) have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company. Heat Biologics is a clinical stage biopharmaceutical company focusing on the development of cancer immunotherapies. OncoSec Medical and Heat Biologics will jointly evaluate the preclinical efficacy of OncoSec’s core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform, with Heat Biologics’ proprietary gp-96-Ig based ImPACT immunotherapy platform.

Yesterday, OncoSec Medical announced that leadership members will present at a number of high-profile events this month. This includes PEGS - The Essential Protein Engineering Summit, the 2015 Marcum MicroCap Conference, and the Sachs Immuno-Oncology: Business Development & Licensing (BD&L) and Investment Forum.

OncoSec Medical, Inc. (ONCS), closed Tuesday's trading session at $0.269, up 1.51%, on 644,479 volume with 90 trades. The average volume for the last 60 days is 999,779 and the stock's 52-week low/high is $0.261/$0.90.

Claude Resources, Inc. (CLGRF)

Zacks reported previously on Claude Resources, Inc. (CLGRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Claude Resources, Inc. is a gold exploration and mining company. It is a gold producer and additionally engages in the exploration and development of gold mineral reserves and mineral resources. Since 1991, the Company has produced greater than 1,000,000 ounces of gold from its Seabee Gold Operation in northeastern Saskatchewan. In addition, the Company owns 100 percent of the Amisk Gold Project in northeastern Saskatchewan. Claude Resources is based in Saskatoon, Saskatchewan.

The Company’s Seabee Gold operation consists of two producing mines, the Seabee Gold Mine and the Santoy 8 Gold Mine. The Seabee Gold Operation is in the La Ronge Mining District at the north end of Laonil Lake around 125 kilometers northeast of the town of La Ronge, Saskatchewan and roughly 150 kilometers northwest of Flin Flon, Manitoba. The Santoy Lake property is an 11,400 acre (4,566 hectare) claim group. It is next to the Claude/Currie Rose property, approximately 14 kilometers east of Claude’s operating Seabee Mine.

Claude Resources’ Amisk Gold Project is in Saskatchewan near Flin Flon, Manitoba. The property consists of 40,373 hectares. It has been subject to a considerable amount of exploration from the 1960's through the 1990's. Claude Resources revived the project in 2010.

Claude Resources’ Board of Directors announced in November 2014 the appointment of Mr. Brian Skanderbeg as President and Chief Executive Officer of the Company effective November 17, 2014. Mr. Skanderbeg joined Claude Resources in 2007. He was appointed Senior Vice President and Chief Operating Officer (COO) in 2012. He has over 10 years of extensive gold mining and exploration experience.

Last month, Claude Resources announced that the Company attained record gold production of 21,067 ounces during Q1 2015 at its 100 percent owned and operated Seabee Gold Operation in Saskatchewan. This exceeded the prior record of 20,614 ounces of gold set during Q3 2014. The strong first quarter represents an 86 percent increase in gold production versus Q1 2014.

During the quarter, Claude Resources milled 67,249 tonnes at 10.17 grams of gold per tonne. This represents a 4 percent and 77 percent increase from Q1 2014, respectively. Over the last four quarters, the Company has produced 72,707 ounces of gold.

Claude Resources, Inc. (CLGRF), closed Tuesday's trading session at $0.5942, down 1.91%, on 380,745 volume with 70 trades. The average volume for the last 60 days is 215,635 and the stock's 52-week low/high is $0.1259/$0.62.

Praxsyn Corp. (PXYN)

Profit Status, Information Solutions Group, EmergingStockPlays, StockPickVIP, and OtcShortReport reported earlier on Praxsyn Corp. (PXYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Praxsyn Corp. focuses on providing custom compounded non-narcotic, transdermal topical pain medications to industrial health physicians and clinics. Currently, it formulates transdermal creams in its compounding pharmacy, Mesa Pharmacy. The Company has developed a series of topical ointments for pain relief. Praxsyn is working on establishing its Point of Care/In-Office Dispensing Program, and its’ In-Office Toxicology Testing. NexGen Med Solutions, LLC is a wholly-owned subsidiary of Praxsyn. Praxsyn is headquartered in Irvine, California.

Praxsyn’s Point-Of-Care Services will provide the health care provider with pharmaceuticals and testing services, which are convenient and easy for physicians and staff. The Company’s wholly-owned subsidiary, Mesa Pharmacy, Inc., provides doctors with an alternative to oral pain medications. Mesa Pharmacy centers on providing custom compounded non-narcotic, transdermal topical pain medications. These are marketed to industrial health physicians and medical clinics.

Mesa Pharmacy has developed a series of topical creams, in different strengths. The transdermal creams are tailored to patients suffering from long-term pain associated with work place related injuries. Praxsyn, via Mesa Pharmacy, provides a series of formulations that are compounded by using Food and Drug Administration (FDA) approved pain medications formulations to help patients suffering from pain associated with injuries. Through compounding, a patient can receive medication exactly formulated for his or her requirements and medical history.

Praxsyn’s NexGen Med Solutions is a billing and collections company. NexGen formed to enable Praxsyn to manage its accounts receivables in a more cost-effective and efficient manner. The expectation is that this new subsidiary will provide an integrated alternative to prior billing and collections procedures.

Praxsyn has begun to process Preferred Provider Organization (PPO) prescriptions. Mesa Pharmacy’s dedication is to providing medical practitioners with medications for patients through this move into the PPO network with its new and advanced products. Mesa has now expanded its innovative and non-addictive product line beyond topical creams to also include capsules, patches, as well as shampoos.

In April, Praxsyn announced that its’ Mesa Pharmacy entered into a Business Associate Agreement with Products for Doctors for marketing and other services on January 23, 2015. The non-exclusive agreement between Products for Doctors and Mesa facilitates the marketing of Mesa Pharmacy’s products to medical providers throughout the State of California.

Praxsyn Corp. (PXYN), closed Tuesday's trading session at $0.0353, up 20.48%, on 1,378,941 volume with 35 trades. The average volume for the last 60 days is 1,031,294 and the stock's 52-week low/high is $0.0252/$0.0995.

Baristas Coffee Company, Inc. (BCCI)

PennyStockRumors.net and PricelessPennyStocks reported earlier on Baristas Coffee Company, Inc. (BCCI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kent, Washington-based Baristas Coffee Company, Inc. formed to create a national brand of drive-thru espresso stands. The Company is accomplishing this through acquiring established businesses that fit its model, opening new locations, and by franchising. Baristas Coffee Company is the largest and fastest growing costume-themed drive through Espresso Company in the nation. Baristas has also now started opening locations in shopping malls. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Baristas Coffee Company can be found in seven greater Seattle area locations, and also in Florida, and Montana. It has company owned locations and has commenced franchising. The Company has its theme of joining attractive female baristas in entertaining costumes preparing premium beverages. Baristas provides its customers hot and cold beverages, specializing in specialty coffees, blended teas, and other custom drinks.

Furthermore, the Company offers smoothies, fresh-baked pastries, as well as other confections. In season, it adds beverages including hot apple cider, hot chocolate, frozen coffees, and more. Another revenue stream for Baristas is in promoting and selling Baristas™ merchandise; alluring calendars, mugs, t-shirts, and hats.

Last week, Baristas Coffee Company announced that its third shopping mall location has started its remodel in Johnstown, Pennsylvania, with eight state master franchise partner BMOC Partners. The location is a 1,000-square-foot inline space at the Johnstown Mall, Johnstown, Pennsylvania. BMOC is a regional hospitality and Franchise operations enterprise. BMOC’s founders have wide-ranging experience in creating, marketing, and running multiple franchise systems.

Mr. Barry Henthorn, Chief Executive Officer, stated, "The third opening of our new mall concept that encompasses not only Baristas famous specialty coffees but also a variety of food items such as the Hale and Hearty soup line is being embraced by the malls management and neighboring retail stores. The new location is just one of many that are in various stages of development and will represent the third location opened in under 60 days."

Baristas Coffee Company, Inc. (BCCI), closed Tuesday's trading session at $0.0358, down 2.19%, on 812,918 volume with 77 trades. The average volume for the last 60 days is 1,686,650 and the stock's 52-week low/high is $0.025/$0.1305.

Net Talk.com, Inc. (NTLK)

Epic Stock Picks, EpicVIP Group, TheMicrocapNews, Greenbackers, and Nebula Stocks reported on Net Talk.com, Inc. (NTLK), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Net Talk.com, Inc. (netTALK) is a foremost ultra-low cost provider of home phone and smartphone communications. The Company’s flagship product is the netTALK DUO. It enables anyone to Fire Your Phone Company® and never pay a monthly phone bill again. The netTALK DUO and the netTALK smartphone app are freeing consumers and small business owners from monthly phone bills and cellular talk minutes. NetTALK is headquartered in Miami Gardens, Florida.

The Company was founded in 2008 by Anastasios “Takis” Kyriakides. His idea was to take advantage of the ongoing technology revolution to give consumers freedom of choice and to free them from outdated, expensive, legacy systems.

netTALK and SHEnetics have a strategic partnership to jointly launch next generation intelligent phone services to netTALK's residential subscribers. The focus of these innovative services are on voice powered personal assistant capabilities for enhanced voicemail, voice dialing, home control, calendaring, alerts, reminders, and web search.

SHEnetics is a pioneer in Artificial Intelligence (AI) based personal digital assistant technology. SHE Simulated Human Experience® is a technology platform for original equipment manufacturers (OEM's) and 3rd party developers to create custom Siri-like intelligent personal digital assistants for any connected device or service.

Yesterday, netTALK and Fantem announced a strategic partnership to provide a cost effective alternative to current home security options. Fantem is the creator of Oomi, an innovative smart home system. The solution, Oomi Personal Home Monitoring powered by netTALK, will provide users peace of mind that their property and loved ones are safe and secure, even when they are not home.

This system uses Oomi's security features and takes advantage of netTALK's communication platform to permit users to proactively monitor their home and communicate with its occupants at a fraction of the cost of other home security solutions. The service will be available as an add-on service to an Oomi smart home system for $60 annually. The Oomi Security Kit combines home security with smart home technology.

Net Talk.com, Inc. (NTLK), closed Tuesday's trading session at $0.009, down 18.18%, on 21,488,491 volume with 295 trades. The average volume for the last 60 days is 847,438 and the stock's 52-week low/high is $0.002/$0.361.

Lyris, Inc. (LYRI)

Zacks and SmallCapVoice reported previously on Lyris, Inc. (LYRI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lyris, Inc. is a worldwide leader of unique email and digital marketing solutions. These solutions help companies reach customers at scale and create personalized value at every point. The Company’s products and services permit marketers to design, automate, as well as optimize experiences that facilitate premier engagement, increase conversions, and deliver measurable business value. Lyris has its corporate headquarters in Emeryville, California.

The Lyris solutions portfolio consists of award-winning messaging automation software, digital marketing strategy and deliverability services, and a componentized and flexible integration framework, which transforms the way marketers can extend digital messaging across the enterprise. Greater than 5,000 companies globally partner with Lyris to manage connected customer communications.

The Company provides retail and ecommerce solutions, agency solutions, media and publishing solutions, enterprise integration solutions. It also provides Lyris Enterprise Connectors, which connects data and digital messaging with the world’s largest choice of applications.

Lyris applications are constructed on a flexible framework. This revolutionizes the ease with which marketers can assemble best-fit configurations of digital marketing capabilities, integrate them across the enterprise, and realize accelerated Return on Investment (ROI) with a lower total cost of ownership.

Yesterday, Lyris announced that it entered into a definitive agreement whereby Aurea, a technology solutions provider that enables companies to deliver transformative customer experiences, will acquire Lyris. With this agreement, each share of outstanding common stock of Lyris will be exchanged for $.89, payable in cash, and each outstanding share of preferred stock of Lyris will be exchanged for $2.50, payable in cash, in accordance with Lyris' charter.

The transaction has been unanimously approved by the Special Committee of the Lyris Board of Directors, and by the entire Lyris Board of Directors. Aurea has more than 1,500 customers globally. These include Disney, British Airways, Bank of America, United Healthcare, and MetLife. Aurea’s Customer Experience platforms helps customers build, execute, monitor, and optimize the total customer journey for a varied range of industries.

Lyris, Inc. (LYRI), closed Tuesday's trading session at $0.865, up 116.25%, on 113,356 volume with 51 trades. The average volume for the last 60 days is 2,239 and the stock's 52-week low/high is $0.25/$2.35.

Plastic2Oil, Inc. (PTOI)

OTC Markets Group reported recently on Plastic2Oil, Inc. (PTOI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 2006, Plastic2Oil, Inc. is a North American fuel company headquartered in Niagara Falls, New York. A clean energy company, it offers technology to recycle waste plastic into liquid fuels, and dirty fuel into clean diesel. The Company’s technology can deliver economic and environmental benefits through replacing refined fuels and diverting waste plastic from landfills.

Plastic2Oil lists on the OTC Markets’ OTCQB. The Company previously went by the name JBI, Inc. It changed its name to Plastic2Oil, Inc. in August of 2014.

Plastic2Oil transforms unsorted, unwashed waste plastic into ultra-clean, ultra-low sulphur fuel without the need for refinement. Its’ patent-pending Plastic2Oil® (P2O®) process is a commercially viable, scalable proprietary process. The design of it is to provide immediate economic benefit for industry, communities, and government organizations with waste plastic recycling challenges.

In addition, Plastic2Oil’s dedication is to the creation of green employment opportunities and a reduction in the cost of plastic recycling programs for municipalities and businesses.

Regarding plastic feedstock supply, Plastic2Oil’s feedstock sources mainly include post-commercial and industrial waste plastic. The P2O processor accepts unwashed, unsorted waste plastic, composites and commingled materials that are difficult to dispose of and are usually found in industrial waste streams. Plastic2Oil believes its P2O process offers a cost-effective, environmental solution for businesses and communities.

In addition, the Company is partnering with businesses and municipalities who collect waste plastics. This waste plastic is normally delivered to independent Material Recycling Facilities (MRFs), where it is frequently sent to landfills. The Company’s goal is to help redirect these waste plastic streams, preventing them from entering local landfills.

Today, Mr. Richard Heddle, Plastic2Oil Chief Executive Officer, issued a letter to the Company’s shareholders. On January 2, 2015, the Company announced that it had contracted to sell up to six processors to EcoNavigation LLC, upon the completion of a pilot study. Subsequently, EcoNavigation presented Plastic2Oil with a number of promising opportunities and now Plastic2Oil and EcoNavigation are involved in multiple, complex negotiations for the potential sale and implementation of P2O processors with several end-users and organizations.

Plastic2Oil, Inc. (PTOI), closed Tuesday's trading session at $0.075, up 4.17%, on 226,349 volume with 25 trades. The average volume for the last 60 days is 71,643 and the stock's 52-week low/high is $0.05/$0.19.


The QualityStocks
Company Corner


Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.005, up 66.67%, on 100,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 92,399, and its 52-week low/high is $0.0013/$0.018.

Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.

Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.

Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Signs License Agreement With NYG Holdings

Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited

Consorteum Holdings Launches New Mobile Results App for Popular Keno Game

Cleartronic, Inc. (CLRI)

The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.11, up 11.22%, on 105,716 volume with 24 trades. The stock’s average daily volume over the past 60 days is 7,487, and its 52-week low/high is $0.04/$0.5499.

Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.

VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.

A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.

Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer

Cleartronic, Inc. Company Blog

Cleartronic, Inc. News:

Cleartronic, Inc. (CLRI) Breaks 40 Million in Radio Transmissions as Both Customer Base and Transmissions Continue Rapid Growth

Cleartronic, Inc. (CLRI) Adds Shareholder Value With Cancellation of Two Billion Shares of Common Stock Held by CEO

Cleartronic Announces Expanded License Agreement With Collabria LLC

Save The World Air, Inc. (ZERO)

The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.41, off by 4.65%, on 139,022 volume with 42 trades. The stock’s average daily volume over the past 60 days is 110,188, and its 52-week low/high is $0.3401/$0.86.

Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.

In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.

The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.

STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.

Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer

Save The World Air, Inc. Company Blog

Save The World Air, Inc. News:

STWA Selected as a Finalist for the 2015 Global Petroleum Show Awards

STWA Reports 2014 Year-End Financial Results and Provides Operational Update

STWA Sets Date for Its Year-End 2014 Earnings Results Release and Conference Call

Inventergy Global, Inc. (INVT)

The QualityStocks Daily Newsletter would like to spotlight Inventergy Global, Inc. (INVT). Today, Inventergy Global, Inc. closed trading at $0.36, off by 2.68%, on 196,098 volume with 829 trades. The stock’s average daily volume over the past 60 days is 392,829, and its 52-week low/high is $0.305/$9.90.

Inventergy Global, Inc. (INVT) is an intellectual property (IP) licensing partner specializing in IP value creation. Led by industry veteran Joe Beyers, former head of global licensing for Hewlett-Packard, Inventergy identifies, acquires and licenses patented technologies to help market-leading technology companies monetize and achieve more value from their innovations.

With more than 100 years of combined experience and track record of handling more than $15 billion in IP and technology transactions, Inventergy’s team of professionals handle every aspect of the IP business, from valuation and branding through legal analysis, decision making and patent sales.

Inventergy partners with world-class, market-significant companies who may lack internal manpower, budget or other resources necessary to realize appropriate return-on-investment. Through collaborative, business-centered, and forward-thinking strategies, Inventergy is able to create portfolios with significant market potential and optimize the innovator’s overall return-on-investment.

The company has established a network of key industry relationships to complement its solid licensing model and growing portfolio of assets, which currently stands at more than 760 global patent assets. Inventergy pursues maturing telecommunications technologies already adopted in the marketplace and earning accretive value. Disclaimer

Inventergy Global, Inc. Company Blog

Inventergy Global, Inc. News:

Inventergy Issued New Patent for Data Transmission Enhancement

Inventergy Strengthens Its Financial Management and Investor Relations (IR) Processes

Inventergy Announces $2.15 Million Common Stock Financing to Accelerate Licensing Operations

Loans4Less.com, Inc. (LFLS)

The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.10, even for the day. The stock’s average daily volume over the past 60 days is 4,503, and its 52-week low/high is $0.015/$0.18.

Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.

Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.

The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.

Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulted on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer

Loans4Less.com, Inc. Company Blog

Loans4Less.com, Inc. News:

LOANS4LESS.COM Enters into an Acquisition Agreement with 321LEND

Loans4Less.com, Inc. Enters into an Investment Banking Agreement with WestPark Capital, Inc. and Seeks Bank Strategic Partner for National Mortgage Broker Origination and Brand Exposure Opportunity

Loans4Less.com Seeks a Merger, Joint Venture Partner and/or Investor for National Loan Origination and Brand Exposure Opportunity

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.00, even for the day. The stock’s average daily volume over the past 60 days is 657, and its 52-week low/high is $3.16/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.058, even for the day. The stock’s average daily volume over the past 60 days is 8,973, and its 52-week low/high is $0.032/$0.29.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding Achieves Positive Net Income From Operations in 2014

MIT Holding (MITD) Launches New Website with Investor Relations Suite

MIT Holding, Inc. Names Tommy J. Duncan as President


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Bull Trends



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251